3 These data suggest that the doxylamine-pyridoxine combination is not only capable

of eradicating mild and moderate forms of NVP, but also of preventing severe cases. Data presented by Neutel reiterate these findings: during the 1990s the increased use of the pyridoxine-doxylamine combination by Canadian women has been associated with a reduction in the hospitalization rates for severe NVP. In conclusion, with the availability of a safe and effective FDA-approved drug for NVP, there is no reason for women to be exposed to a drug of unproven maternal and fetal safety, which has not been labeled for NVP. “
“Two statistics were incorrect in the study results provided in a research paper published in October 2011 (McDonald SD, Pullenayegum E, Taylor VH, et al. Despite 2009 guidelines, few women report being counseled correctly about CT99021 in vivo weight gain during pregnancy. Am J Obstet Gynecol 2011;205:333.e1-6.). In Table 2, “Patient perception of

prenatal counseling recommendations” (page 333.e3), under the heading “Respondents, n (%)” for subjects who “Were counseled selleck kinase inhibitor to consume an amount or range of additional calories each day by health care provider” (sixth category under Outcome), the correct total is 55 (17.9), not 253 (17.9), as published. (The total is 55 because values were missing for 5 subjects.) The Results section of the text, beginning with the final paragraph in column 1 on page 333.e4, states: “Fewer than 1 in 5 patients (17.7%) reported that their health care provider

recommended that they eat a specific range of additional calories each day; one-third of them could not recall the amount that had been recommended.” The correct percentage is 17.9%. “
“Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Am J Obstet Gynecol Liothyronine Sodium 2012;206:300–8. In a 2012 SMFM Clinical Guideline on Doppler assessment of the IUGR fetus, the key to abbreviations of a flowchart included an error. In Figure 5, “Algorithm for clinical use of Doppler ultrasound in management of suspected IUGR” (page 306), “UA,” used in 3 boxes in the flowchart, was incorrectly identified as “uterine artery.” The spellout in this context should have been “umbilical artery. The error was perpetuated in the legend for the same flowchart, renamed Figure 6, in a subsequent republication of the slightly revised paper in another journal (Copel JA, Bahtiyar MO. A practical approach to fetal growth restriction. Obstet Gynecol 2014;123:1057-69). A correction has been published in that journal as well. “
“It was stated in the March 2014 issue of the Journal that no reprints were available from the authors of a research article (Zhang W-x, Jiang H, Wang X-m, et al. Pregnancy and perinatal outcomes of interventional ultrasound sclerotherapy with 98% ethanol on women with hydrosalpinx before in vitro fertilization and embryo transfer.